- Home
- NTHI vs HURA Comparison
NTHI vs HURA Comparison
Compare NTHI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- HURA
- Stock Information
- Founded
- NTHI 2008
- HURA 2009
- Country
- NTHI United States
- HURA United States
- Employees
- NTHI N/A
- HURA N/A
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- HURA
- Sector
- NTHI Health Care
- HURA
- Exchange
- NTHI Nasdaq
- HURA Nasdaq
- Market Cap
- NTHI 110.9M
- HURA 103.3M
- IPO Year
- NTHI N/A
- HURA N/A
- Fundamental
- Price
- NTHI $5.10
- HURA $2.85
- Analyst Decision
- NTHI
- HURA Strong Buy
- Analyst Count
- NTHI 0
- HURA 2
- Target Price
- NTHI N/A
- HURA $11.50
- AVG Volume (30 Days)
- NTHI 284.4K
- HURA 427.2K
- Earning Date
- NTHI 01-01-0001
- HURA 08-15-2025
- Dividend Yield
- NTHI N/A
- HURA N/A
- EPS Growth
- NTHI N/A
- HURA N/A
- EPS
- NTHI N/A
- HURA N/A
- Revenue
- NTHI $79,990.00
- HURA N/A
- Revenue This Year
- NTHI N/A
- HURA N/A
- Revenue Next Year
- NTHI N/A
- HURA $69.15
- P/E Ratio
- NTHI N/A
- HURA N/A
- Revenue Growth
- NTHI 13.52
- HURA N/A
- 52 Week Low
- NTHI $3.20
- HURA $1.80
- 52 Week High
- NTHI $25.00
- HURA $9.01
- Technical
- Relative Strength Index (RSI)
- NTHI N/A
- HURA N/A
- Support Level
- NTHI N/A
- HURA N/A
- Resistance Level
- NTHI N/A
- HURA N/A
- Average True Range (ATR)
- NTHI 0.00
- HURA 0.00
- MACD
- NTHI 0.00
- HURA 0.00
- Stochastic Oscillator
- NTHI 0.00
- HURA 0.00
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.